SCHEDULE: Feinstein Entities Acquire Hepion Pharma Stake

Black Global 5 LLC, Red Global 3, LLC, and Darin Feinstein have jointly filed a Schedule 13D, reporting beneficial ownership of 10,000,000 shares of Hepion Pharmaceuticals, Inc. common stock, representing 11.1% of the class.

Summary

• Black Global 5 LLC, Red Global 3, LLC, and Darin Feinstein (collectively, the 'Reporting Persons') have filed a Schedule 13D regarding their beneficial ownership of Hepion Pharmaceuticals, Inc. common stock.
• Black Global 5 LLC acquired 10,000,000 shares of common stock and one warrant to purchase an additional 10,000,000 shares for $500,000 on July 31, 2026.
• The purchase price was funded by Black Global's working capital.
• The warrant is immediately exercisable but subject to a Beneficial Ownership Limitation, preventing exercise if it would cause Black Global to exceed ownership thresholds.
• The Reporting Persons collectively beneficially own 10,000,000 shares, representing approximately 11.1% of Hepion Pharmaceuticals' outstanding common stock (based on 90,220,317 shares outstanding).
• The acquisition was for investment purposes, with the intention to continuously review the investment.
• The Reporting Persons may acquire additional securities, dispose of existing holdings, or maintain their current position based on market conditions and other factors.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral to slightly negative score due to the acquisition of shares at a discount and the presence of a warrant with limitations, indicating potential dilution and a need for further capital. The filing primarily details ownership changes rather than operational performance.

Positives

• Acquisition of a significant stake (11.1%) in Hepion Pharmaceuticals, Inc. by the Reporting Persons.
• The purchase price of $500,000 for 10,000,000 shares and a warrant suggests a discounted acquisition price.
• The Reporting Persons have the flexibility to potentially acquire more shares or dispose of their current holdings based on future assessments.

Negatives

• The warrant to purchase additional shares is subject to a Beneficial Ownership Limitation, restricting its immediate full exercise.
• The need for a warrant with limitations may suggest future capital needs or dilution concerns for existing shareholders.
• The filing indicates an investment purpose, but the specific strategy or long-term goals beyond 'reviewing the investment' are not detailed.

Risks

• The Beneficial Ownership Limitation on the warrant could prevent the Reporting Persons from fully exercising their rights, potentially impacting future share counts and ownership percentages.
• Future decisions to acquire additional securities or dispose of existing holdings could lead to increased share price volatility.
• The investment purpose, without further defined plans, leaves the company's strategic direction influenced by external investors' ongoing reviews.

Future Outlook

The Reporting Persons intend to review their investment in Hepion Pharmaceuticals, Inc. on a continuing basis. Depending on market conditions, the Issuer's business, financial condition, prospects, general economic conditions, and other factors, they may acquire additional securities, dispose of some or all of their securities, or maintain their current investment position. No specific future plans beyond this review are currently disclosed.

Industry Context

StockSavvy.ai notes that Schedule 13D filings typically signal a significant change in beneficial ownership, often indicating a strategic interest from an investor. For a company like Hepion Pharmaceuticals, which operates in the biotechnology sector, such filings can precede activist campaigns, takeover attempts, or simply a substantial investment by a financial entity.

Stakeholder Impact

• Shareholders: Potential for increased share price volatility due to the Reporting Persons' stated intention to review and potentially adjust their investment position. The limited warrant exercise could also be a point of concern regarding future dilution.
• Creditors: No direct impact mentioned, but significant changes in ownership or strategy could indirectly affect the company's financial stability.
• Management: May face increased scrutiny or engagement from the Reporting Persons regarding company strategy and performance.

Next Steps

• Reporting Persons will continue to review their investment in Hepion Pharmaceuticals, Inc.
• Potential future actions include acquiring additional securities, disposing of existing securities, or maintaining the current investment position.

Key Dates

Recommendation

The filing indicates a significant investment by new entities, but the purpose is stated as 'investment purposes' with a plan to review. The acquisition was at a discount, and the warrant has limitations. Without more clarity on the Reporting Persons' strategic intentions or the company's operational performance, a 'hold' recommendation is prudent, awaiting further developments or disclosures.

Keywords

Schedule 13D, Hepion Pharmaceuticals, Black Global 5 LLC, Red Global 3, LLC, Darin Feinstein, Beneficial Ownership, Securities Purchase Agreement, Warrant